InMed Pharmaceuticals Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York.
The company's management team will engage in one-on-one investor meetings during the conference.
A corporate presentation will be available online for investors to access.
Pipeline Development Focus
InMed is focused on developing proprietary small molecule drug candidates for diseases with high unmet medical needs.
Conference Participation
InMed will be participating in the H.C. Wainwright 27th Annual Global Investment Conference in New York.
INM-901 Program Update
Recent data from INM-901 program in the treatment of Alzheimer's was presented at AAIC 2025.
- InMed's focus on developing drug candidates for Alzheimer's and other indications highlights its commitment to addressing medical needs.
- Participation in investment conferences like H.C. Wainwright enhances visibility and investor engagement for the company.
InMed's proactive approach to pipeline development and participation in key industry events position it for continued growth and innovation in the pharmaceutical sector.